News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
EUnetHTA21 Launches Joint Scientific Consultations for Regulators, HTAs, and Sponsors
The aim of the new health technology assessment (HTA) regulation is to secure timely patient access to novel therapies, to avoid duplicative HTA-assessment work at the Member State level, and to provide the sector with a predictable and consistent HTA process.